top of page

Possible Breakthrough in treatment of alcohol abuse with the use of semaglutides / GLP-1 Medications.



Paul Kolodzik, MD, FACEP, FASAM

Board Certified in Addiction Medicine

For nearly 100 years the primary treatment offered to patients seeking help for excessive drinking, sometimes the only treatment offered, has been abstinence. The whole industry of inpatient and residential alcohol rehabilitation is built on this model. Though a minority of patients seek and achieve abstinence for life, a majority of patients seeking abstinence experience multiple periods of abstinence followed by multiple relapses. Sometimes the periods of relapse and associated abuse last for years. I believe it is time to look at a more advanced medical model for the treatment of alcohol use disorder (formerly called alcoholism). 

We do not treat cancer or heart disease the same way as we did in the 1920s. Why should we treat substance use disorders like we did 100 years ago?

                                                                     HARM REDUCTION

The concept of “harm reduction” is the approach of seeking a reduction in alcohol use, and not necessarily complete abstinence. As a Board-Certified Addictionologist I have treated hundreds of patients successfully with this approach.  Some of these patients, after they have reduced their alcohol use, go on to abstinence. Most continue limited alcohol use with volume intakes greatly reduced and well within established guidelines. 

                                              MEDICATIONS THAT REDUCE ALCOHOL USE

In the majority of my patients, I treat I utilize a medication, or multiple medications, to help reduce their alcohol use. I also employ many of the other standard techniques to assist with reducing the amount of alcohol consumed. These include daily and weekly drinking limit goals, journalizing of drink volumes (drink logs), managing “persons, places, and things” variables, stress reduction, and even, at times, Alcoholics Anonymous or Smart Recovery. practices if applicable, etc.

There are three medications approved by the FDA for the treatment of alcohol use disorder. I believe a fourth will approved in coming years which is already being used by some clinicians because of early evidence of its effectiveness. These medications include:

  • Disulfiram (Antabuse): This medication is taken daily, and then if alcohol is consumed a physiological reaction occurs causes illness – mostly nausea and vomiting. Some serious reactions have occurred with this “punitive” negative reinforcement technique. I do not use Disulfiram.

  • Acamprosate (Campral): Improves prolonged abstinence in only one out of eight patients. It is dosed as two pills three times a day, so conforming to this regimen is difficult. Because of the limited efficacy and difficulty in getting patients to be compliant with this medication, I do not use it routinely.

  • Naltrexone: This medicine is a “brain pleasure receptor blocker” (Reduces the “pleasurable effects” of intrinsic or endogenous opiates (endorphins and enkephalilins, dopamine and serotonin.) The result is a reduction of the pleasurable “warm and fuzzy” feeling associated with alcohol use. I have used this medication for years and it can help greatly in reducing alcohol volume intake (see more below). It can be prescribed daily by pill, monthly by injection, or intermittently only on days that alcohol is ingested. The last approach is called the “Sinclair Method” and I have used it successfully in my addiction medicine practice for the last 10 years. Naltrexone is an inexpensive generically available medication. 

  •  . . . and then there is semaglutide (Wegovy, Ozempic).


Semaglutide is not yet approved for reducing alcohol use. However, with the increased use of these medications for diabetes and weight loss it is becoming evident that this medicaiton reduces alcohol cravings in addition to food cravings. Rather than me enumerate the information out there on this subject, just Google ‘semaglutide and alcohol”. You will find dozens of articles supporting the use of semaglutide to reduce alcohol use. Though no “double blinded peer review studies” (the gold standard in medical research) have been published on this subject, several are in process. There are many case studies series, anecdotal results of a small number of patients, affirming significant alcohol use reduction. Numerous animal studies (mostly with rats) also confirm the mediations likely efficacy.

As an aside, my comments about semaglutide also generally apply to other “GLP-1” medications used to treat obesity such as Tirzepatide (Manjouro, Zepbound), liraglutide (Saxenda) and others.  

And then I have my personal clinical experience. I have treated hundreds of patients with semaglutide for the indications of diabetes and/or obesity, and the result related to alcohol use reduction is clear to me. Nearly universally, alcohol use is significantly reduced in those who previously reported they were drinking “too much”. And it is also reduced even in those who did not have any issues with alcohol. Patients, along with their reduced hunger on these meds, indicate little or no desire for alcohol.  I have had patents drinking too much (for example 30 drinks or more a week) who routinely cut their drinking in more than half, or even stopped drinking. And I have had many patients who were drinking in the acceptable range (15 drinks a week for men and 7 drinks a week for women) who all but eliminated or did eliminate their alcohol use altogether. 



The answer is “yes and no”. If a person uses too much alcohol, but also meets the diabetic or Body Mass Index (BMI) obesity/ overweight criteria for semaglutide use per the FDA criteria, they may be prescribed the medication.  It is being prescribed for the FDA-approved indication, with the knowledge of both the physician and the patient that it will also result in lower alcohol intake. Though “off label” use is common (prescribing a medication for a use that is not FDA approved for), I do not know any medical providers who are prescribing this medication for patients not meeting diabetic or Body Mass Index criteria. However, I think this will become common in the future, once some peer review studies proving the effectiveness of this therapeutic modality for alcohol use disorder have been published. 

I currently am only prescribing semaglutide to help patents reduce alcohol use . . . so long as they meet one of the other FDA criteria.

                                                       INSURANCE AND COST ROADBLOCKS

Medications are often not covered by insurance when the indication they are being prescribed for is “off label”, or not FDA-approved.  Furthermore, a tis time semaglutide has very limited insurance coverage for the treatment of overweight/obesity, meaning most people do not have this medication on their health care coverage pharmacy formulary. (The exception is that Ozempic is often covered, but only for patients with a true diagnosis of diabetes.)  If not covered, patients must pay the full “out of pocket” cost for the brand name medication (in this case Wegovy). Out of pocket costs for these medications are commonly more than $1,000 per month. Fortunately, generic “compounded” medications are availble at about a third the cost for patients who do not have insurance coverage for the brand name medications. Semaglutide is usually compounded with vitamin B12. Compounded medications are also usually not covered by insurance, nor are they FDA approved. They are manufactured in the US by state licensed pharmacies.  


I have treated a number of patients to help them reduce alcohol use with medications over the last decade. For much of this time I have utilized primarily The Sinclair Method using naltrexone, and have had very good results. Recently, since semaglutide has become available, I have treated a number of patients with the combination of semaglutide and The Sinclair Method. In combination with standard behavioral techniques (drink log, etc. discussed above) I have found this combination to be more effective than any other approach to reducing or eliminating alcohol use. It is rare for a patient to not significantly reduce alcohol use with this approach. As stated above, at this time I only add semaglutide to this regimen if the patient is diabetic or meets BMI criteria.

If you are interested in learning more about the use of medications to reduce alcohol use, please contact the North Dayton Addiction and Recovery office. 

2 views0 comments


bottom of page